


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing Of Claims:

WHAT IS CLAIMED IS:

1. A compound having the Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

Q_1 and Q_2 are independently =O, =S, =NH or =N-NHR, where R is -H, -C₁-C₁₀ alkyl, or -aryl;

Q_3 is -O-, -S-, or -N(H)-;

R_1 and R_2 are independently -H, -halogen, -amino, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, (C₃-C₇) cycloalkyl, -aryl, C₁-C₁₀ (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1 , R_2 and the carbon atom to which they are both attached are taken together to form a (C₃-C₇) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR₃; B is N or CR₄; D is N or CR₅; E is N or CR₆, at least one of A, B, D and E being CR₃, CR₄, CR₅ or CR₆, respectively;

each R_3 , R_4 , R_5 and R_6 is independently -H, -halogen, -CN, -NH₂, -NO₂,

-COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -

C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCH₂OR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -S(O)₂NHR₁₁, -SOR₁₁, -S(O)₂R₁₁, -NHC(O)R₁₁, -NHSOR₁₁, or NHS(O)₂R₁₁; or

R₃ and R₄ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₅ and R₆ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₄ and R₅ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R₇ is -H, -C₁-C₁₀ alkyl, or -C₁-C₁₀ alkoxy;

R₈ and R₉ are each independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -SOR₁₁, -S(O)₂R₁₁, -S(O)₂NHR₁₁, -NHSR₁₁, -NHSOR₁₁, or -NHS(O)₂R₁₁;

R₁₀ is -H, -C₁-C₁₀ alkyl, -C₃-C₇ cycloalkyl, -C(O)C₁-C₁₀ alkyl, -C₁-C₁₀ (oxy)alkyl, -C(O)NH₂, -C(O)NHR₁₂, or -aryl;

R₁₁ is -H, -C₁-C₁₀ alkyl, -(C₃-C₇) cycloalkyl, -C₁-C₁₀ (halo)alkyl, -aryl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -C₁-C₁₀ (aryl)alkyl, -C₂-C₁₀ (aryl)alkenyl, -C₂-C₁₀ (aryl)alkynyl, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (amino)alkyl,

a -(C₃-C₇) cycloalkyl unsubstituted or substituted with one or more -C₁-C₁₀ alkyl,


a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C₁-C₁₀ alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more $-C_1-C_{10}$ alkyl, $-C_2-C_{10}$ alkenyl, or $-C_2-C_{10}$ alkynyl;


R_{12} is C_1-C_{10} alkyl; and

each halogen is independently $-F$, $-Cl$, $-Br$ or $-I$;

with the proviso that the compound of Formula (I) is not:




10-Hydroxy-6-methoxy-1,1,4a,7-tetramethyl-1H,4aH-phenanthrene-2,9-dione; or





10-Hydroxy-7-hydroxymethyl-6-methoxy-1,1,4a-trimethyl-1H,4aH-phenanthrene-2,9-dione, or a pharmaceutically acceptable salt thereof.

2. A compound of the formula:






;



or a pharmaceutically acceptable salt thereof, the compound or pharmaceutically acceptable salt thereof being in isolated and purified form.

3. A compound of the formula:





or a pharmaceutically acceptable salt thereof, the compound or pharmaceutically acceptable salt thereof being in isolated and purified form.

4. The compound or pharmaceutically acceptable salt of the compound of claim 1, wherein

Q_1 and Q_2 and Q_3 are oxygen;

R_1 and R_2 are C_1 - C_{10} alkyl;





R_8 and R_9 are H;



R_7 is C_1 - C_{10} alkyl;

R_3 and R_6 are H; and


R_4 and R_5 are independently C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, or C_1 - C_{10} (hydroxy)alkyl.




5. A compound having the structure:









6. The compound of claim 1, having the structure:















;




;




;





or a pharmaceutically acceptable salt thereof.

7. A compound having the Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

Q_1 and Q_2 are independently =O, =S, =NH or =N-NHR, where R is -H, -C₁-C₁₀ alkyl, or -aryl;

Q_3 is -O-, -S-, or -N(H)-;

R_1 and R_2 are independently -H, -halogen, -amino, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, (C₃-C₇) cycloalkyl, -aryl, C₁-C₁₀ (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1 , R_2 and the carbon atom to which they are both attached are taken together to form a (C₃-C₇) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR₃; B is N or CR₄; D is N or CR₅; E is N or CR₆, at least one of A, B, D and E being CR₃, CR₄, CR₅ or CR₆, respectively;

each R₃, R₄, R₅ and R₆ is independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCH₂OR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -S(O)₂NHR₁₁, -SOR₁₁, -S(O)₂R₁₁, -NHC(O)R₁₁, -NHSOR₁₁, or NHS(O)₂R₁₁; or

R₃ and R₄ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₅ and R₆ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₄ and R₅ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R₇ is -H, -C₁-C₁₀ alkyl, or -C₁-C₁₀ alkoxy;

R₈ and R₉ are each independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -SOR₁₁, -S(O)₂R₁₁, -S(O)₂NHR₁₁, -NH₂SR₁₁, -NHSOR₁₁, or -NHS(O)₂R₁₁;

R₁₀ is -H, -C₁-C₁₀ alkyl, -C₃-C₇ cycloalkyl, -C(O)C₁-C₁₀ alkyl, -C₁-C₁₀ (oxy)alkyl, -C(O)NH₂, -C(O)NHR₁₂, or -aryl;

R_{11} is -H, -C₁-C₁₀ alkyl, -(C₃-C₇) cycloalkyl, -C₁-C₁₀ (halo)alkyl, -aryl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -C₁-C₁₀ (aryl)alkyl, -C₂-C₁₀ (aryl)alkenyl, -C₂-C₁₀ (aryl)alkynyl, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (amino)alkyl,

a -(C₃-C₇) cycloalkyl unsubstituted or substituted with one or more -C₁-C₁₀ alkyl,


a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C₁-C₁₀ alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more -C₁-C₁₀ alkyl, -C₂-C₁₀ alkenyl, or -C₂-C₁₀ alkynyl;

R_{12} is C₁-C₁₀ alkyl; and

each halogen is independently -F, -Cl, -Br or -I.

8. A compound having the Formula (III):



or a pharmaceutically acceptable salt thereof, wherein:

Q_1 , Q_2 and Q_3 are independently =O, =S, =NH or =N-NHR, where R is -H, -C₁-C₁₀ alkyl, or -aryl;

R_1 and R_2 are independently -H, -halogen, -amino, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, (C₃-C₇) cycloalkyl, -aryl, C₁-C₁₀ (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1 , R_2 and the carbon atom to which they are both attached are taken together to form a (C₃-C₇) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR₃; B is N or CR₄; D is N or CR₅; E is N or CR₆, at least one of A, B, D and E being CR₃, CR₄, CR₅ or CR₆, respectively;

each R₃, R₄, R₅ and R₆ is independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCH₂OR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -S(O)₂NHR₁₁, -SOR₁₁, -S(O)₂R₁₁, -NHC(O)R₁₁, -NHSOR₁₁, or NHS(O)₂R₁₁; or

R₃ and R₄ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₅ and R₆ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₄ and R₅ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R₇ is -H, -C₁-C₁₀ alkyl, or -C₁-C₁₀ alkoxy;

R₈ and R₉ are each independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -SOR₁₁, -S(O)₂R₁₁, -S(O)₂NHR₁₁, -NHSR₁₁, -NHSOR₁₁, or -NHS(O)₂R₁₁;

R₁₁ is -H, -C₁-C₁₀ alkyl, -(C₃-C₇) cycloalkyl, -C₁-C₁₀ (halo)alkyl, -aryl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -C₁-C₁₀ (aryl)alkyl, -C₂-C₁₀ (aryl)alkenyl, -C₂-C₁₀ (aryl)alkynyl, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (amino)alkyl,



a $-(C_3-C_7)$ cycloalkyl unsubstituted or substituted with one or more $-C_1-C_{10}$ alkyl,
a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted
with one or more $-C_1-C_{10}$ alkyl, or


a three- to seven-membered aromatic heterocycle unsubstituted or substituted with
one or more $-C_1-C_{10}$ alkyl, $-C_2-C_{10}$ alkenyl, or $-C_2-C_{10}$ alkynyl;

R_{12} is C_1-C_{10} alkyl; and

each halogen is independently -F, -Cl, -Br or -I.


9. The compound of claim 8 having the formula:





or a pharmaceutically acceptable salt thereof.

10. A compound having the Formula (IV):



or a pharmaceutically acceptable salt thereof, wherein:

Q_1 , Q_2 and Q_3 are independently =O, =S, =NH or =N-NHR, where R is -H, -C₁-C₁₀ alkyl, or -aryl;

R_1 and R_2 are independently -H, -halogen, -amino, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, (C₃-C₇) cycloalkyl, -aryl, C₁-C₁₀ (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1 , R_2 and the carbon atom to which they are both attached are taken together to form a (C₃-C₇) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR₃; B is N or CR₄; D is N or CR₅; E is N or CR₆, at least one of A, B, D and E being CR₃, CR₄, CR₅ or CR₆, respectively;

each R₃, R₄, R₅ and R₆ is independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCH₂OR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -S(O)₂NHR₁₁, -SOR₁₁, -S(O)₂R₁₁, -NHC(O)R₁₁, -NHSOR₁₁, or NHS(O)₂R₁₁; or

R₃ and R₄ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₅ and R₆ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R₄ and R₅ and the carbon atoms to which they are attached are taken together to form a (C₃-C₇) cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R₇ is -H, -C₁-C₁₀ alkyl, or -C₁-C₁₀ alkoxy;

R₈ and R₉ are each independently -H, -halogen, -CN, -NH₂, -NO₂, -COOH, -C(O)NH₂, -SH, -S(O)NH₂, -S(O)₂NH₂, -C₁-C₁₀ (oxy)alkyl, -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ (amino)alkyl, -C₁-C₁₀ (halo)alkyl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -(C₃-C₇) cycloalkyl, -aryl, -C₁-C₁₀ (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH₂OR₁₁, -OCR₁₁, -OC(O)R₁₁, -C(O)R₁₁, -OC(O)OR₁₁, -OC(O)NR₁₁, -C(O)OR₁₁, -C(O)NR₁₁, -OP(O)(OR₁₁)₂, -SR₁₁, -SOR₁₁, -S(O)₂R₁₁, -S(O)₂NHR₁₁, -NHSR₁₁, -NHSOR₁₁, or -NHS(O)₂R₁₁;

R₁₁ is -H, -C₁-C₁₀ alkyl, -(C₃-C₇) cycloalkyl, -C₁-C₁₀ (halo)alkyl, -aryl, -C₂-C₁₀ alkenyl, -C₂-C₁₀ alkynyl, -C₁-C₁₀ (aryl)alkyl, -C₂-C₁₀ (aryl)alkenyl, -C₂-C₁₀ (aryl)alkynyl, -C₁-C₁₀ (hydroxy)alkyl, -C₁-C₁₀ alkoxy, -C₁-C₁₀ (amino)alkyl,

a -(C₃-C₇) cycloalkyl unsubstituted or substituted with one or more -C₁-C₁₀ alkyl,

a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C₁-C₁₀ alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more -C₁-C₁₀ alkyl, -C₂-C₁₀ alkenyl, or -C₂-C₁₀ alkynyl;

R₁₂ is C₁-C₁₀ alkyl; and

each halogen is independently -F, -Cl, -Br or -I.

11-65. (Canceled)

66. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier.

67. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 2 and a pharmaceutically acceptable carrier.

68. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 3 and a pharmaceutically acceptable carrier.

69. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 7 and a pharmaceutically acceptable carrier.

70. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 8 and a pharmaceutically acceptable carrier.

71. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 10 and a pharmaceutically acceptable carrier.

72-103. (Canceled)